Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Helena Earl, Louise Hiller, Anne-laure Vallier, Shrushma Loi, Karen Mcadam, Luke Hughes-davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter HallBethany Shinkins, Christopher Mccabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1-190
JournalHealth Technology Assessment
Issue number40
Publication statusPublished - 2 Sept 2020

Cite this